Loading...
•
Mar 31, 2021
Solid Biosciences Q1 2021 Earnings Report
Solid Biosciences reported first quarter 2021 financial results and provided a business update.
Key Takeaways
Solid Biosciences reported a net loss of $16.9 million for the first quarter of 2021. The company's cash and cash equivalents were $268.5 million as of March 31, 2021, expected to fund operations into Q4 2022. Patient 8 in the IGNITE DMD trial experienced a serious adverse event.
Patients 7 and 8 were dosed in the IGNITE-DMD Phase I/II clinical trial under a new clinical protocol and second-generation SGT-001 manufacturing process.
Patient 8 experienced a serious adverse event.
Long-term biopsy data from the ongoing IGNITE DMD trial demonstrated durable microdystrophin expression up to two years post dosing of SGT-001.
The company ended Q1 with $268.5 million in cash, providing a cash runway into Q4 2022.
Forward Guidance
Solid Biosciences expects that its cash and cash equivalents will enable the company to fund its operating expenses and capital expenditures into the fourth quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...